EVOKE PHARMA INC (EVOK) Stock Income Statement
NASDAQ:EVOK - Nasdaq - US30049G3020 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.59M | 10.25M | 5.18M | 2.51M | 1.62M | |||
| Cost Of Goods | 305.60K | 356.50K | 201.90K | 370.00K | 330.00K | |||
| Gross Profit | 11.29M | 9.89M | 4.98M | 2.14M | 1.29M | |||
| Operating Expenses | 16.29M | 15.10M | 12.41M | 9.92M | 9.44M | |||
| Research and Development | 54.50K | 16.30K | 181.90K | 300.00K | 590.00K | |||
| Selling, General, and Administrative Expenses | 16.24M | 15.08M | 12.23M | 9.62M | 8.85M | |||
| Operating Income | -5.00M | -5.20M | -7.43M | -7.79M | -8.15M | |||
| Interest Income/Expense | -73.90K | -148.10K | -361.40K | -440.00K | -490.00K | |||
| Other Income/Expense | N/A | N/A | N/A | 0.00 | 110.00K | |||
| Income Before Taxes | -5.08M | -5.35M | -7.79M | -8.22M | -8.54M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -5.08M | -5.35M | -7.79M | -8.22M | -8.54M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.72 | -2.81 | -27.97 | -2.62 | -3.18 | |||
| Non GAAP EPS | -3.01 | -4.54 | -27.96 | -32.16 | -38.88 | |||
| Statistics | ||||||||
| Gross Profit Margin | 97.36% | 96.52% | 96.10% | 85.26% | 79.63% | |||
| Profit Margin | -43.80% | -52.22% | -150.41% | -327.49% | -527.16% | |||
| Operating Profit Margin | -43.17% | -50.77% | -143.44% | -310.36% | -503.09% | |||
All data in USD